In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic.
Ramos
E L
EL
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Leggat
J E
JE
Milford
E L
EL
Kirkman
R L
RL
Tilney
N L
NL
Strom
T B
TB
Shapiro
M E
ME
Waldmann
T A
TA
Carpenter
C B
CB
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D016030:Kidney Transplantation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D016032:Randomized Controlled Trials as Topic; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2